Details for Patent: 10,370,406

Which drugs does patent 10,370,406 protect, and when does it expire?

Patent 10,370,406 protects BREXAFEMME and is included in one NDA.

This patent has fifteen patent family members in thirteen countries.

Summary for Patent: 10,370,406

Title:	Salts and polymorphs of SCY-078
Abstract:	SCY-078 is a glucan synthase inhibitor with antimicrobial activity. Novel salts and polymorph forms of SCY-078 are disclosed herein. The disclosure also relates to pharmaceutical compositions, methods of use, and methods of preparing the novel salts and polymorphs of SCY-078.
Inventor(s):	Zhang; Yi (Suzhou, CN)
Assignee:	SCYNEXIS, INC. (Jersey City, NJ)
Application Number:	16/203,273
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 10,370,406

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Scynexis	BREXAFEMME	ibrexafungerp citrate	TABLET;ORAL	214900-001	Jun 1, 2021		RX	Yes	Yes						TREATMENT OF ADULT AND POST-MENARCHAL PEDIATRIC FEMALES WITH VULVOVAGINAL CANDIDIASIS (VVC)

International Family Members for US Patent 10,370,406

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Denmark	3247711
Eurasian Patent Organization	036874
Eurasian Patent Organization	201791645
European Patent Office	3247711
European Patent Office	4039684
Spain	2913111
Hong Kong	1247196